Forging a path to reimbursement for ground-breaking medicines
We helped our client, a leading pharmaceutical company, to strike a ground-breaking agreement so that people with aggressive cancers could benefit from the first in a new wave of personalised cancer therapies.
Using our insight and experience, we identified the commercial and assessment challenges that the therapy would present, reflecting on the varied needs of commissioners, clinicians and researchers alike. This in-depth analysis facilitated the engagement with advocates and key stakeholders that was required to collaboratively develop the solutions that would achieve rapid access for patients. The result is the first such reimbursement agreement in Europe.